Royalty Report: Drugs, Diagnostic, Pharmaceuticals – Collection: 26859

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Diagnostic
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Medical
  • Device
  • Surgical
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26859

License Grant
The Company obtained from a Canadian manufacturer of radiopharmaceuticals, the right to develop and market Viascint in the United States.  Upon FDA approval, the Company may sublicense the marketing rights for Viascint.
License Property
Viascint – a sterile radiopharmaceutical formulation of iodine123-iodophenylpentadecanoic acid for injection – subject to FDA approval, as to which no assurance can be given, proposed to be used to determine the presence of hibernating, or reversibly injured heart muscle and thereby predict which patients are most likely to experience improvement in cardiac function following, and thus benefit from, coronary artery bypass graft (CABG) surgery, and to assist physicians in the selection of patients for such surgery.

The Company completed Phase III clinical testing, and the results indicated that the product provides the means to predict, with high accuracy, which patients will have improvement in cardiac functioning following revascularization. The Company filed an NDA in 1996.

Field of Use
The rights granted apply to the heart muscle.

IPSCIO Record ID: 27250

License Grant
The Company granted an exclusive license to manufacture and market Adenocard in the United States and Canada.  Adenocard(R) – a sterile formulation of adenosine for injection indicated for the  treatment of abnormally rapid heartbeats originating in the upper chambers of the heart, so-called paroxysmal supraventricular tachycardia.
License Property
Adenoscan is a sterile formulation of adenosine (3mg/ml) available in 30ml or 20ml vials for infusion indicated as an adjunct to thallium cardiac imaging in the evaluation of coronary artery disease.  Adenoscan is used by doctors to help diagnose heart disease.  The drug is used by doctors to simulate stress for elderly patients and others who cannot exercise on a treadmill.  In October 1988, the Company completed clinical trial and received FDA approval to market Adenocard in the United States.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 26514

License Grant
The Company granted a French pharmaceutical company the exclusive rights to manufacture and market Adenoscan worldwide except in the United States, Canada, Japan, Korea and Taiwan.  In June 1995, the Licensee received marketing approval for Adenoscan in the United Kingdom and in February 1997.
License Property
Adenoscan® – a sterile formulation of adenosine for infusion – indicated as an adjunct to thallium cardiac imaging for the evaluation of coronary artery disease in patients unable to exercise adequately, so-called pharmacological stress.  Commercially available from Fujisawa in the United States and Canada since 1995.  In May 1995, the Company complete clinical trial and received from the FDA marketing clearance for Adenoscan in the United States.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 26861

License Grant
The Company granted a pharmaceutical company an exclusive license in the United States and Canada to manufacture and market Adenoscan. Adenoscan® – a sterile formulation of adenosine for infusion – indicated as an adjunct to thallium cardiac imaging for the evaluation of coronary artery disease in patients unable to exercise adequately, so-called pharmacological stress.  Commercially available from the Japanese pharmaceutical company in the United States and Canada since 1995, the drug also is sold by Sanofi in the United Kingdom and pending registration and approval in other countries of the world.  The Company completed clinical trial and received from the FDA marketing clearance for Adenoscan in the United States.  In May 1995, the Company complete clinical trail and received from the FDA marketing clearance for Adenoscan in the United States.

IPSCIO Record ID: 27406

License Grant
The Company, in its acquisition of technology in 1993 related to its TMR therapy from the University.  Under this agreement, the Company has a worldwide exclusive license to any patents that issue in connection related with cardiac revascularization technology for the treatment of advanced cardiovascular disease and severe angina pain through transmyocardial revascularization, TMR.
License Property
TMR is a treatment aimed at improving blood flow to areas of the heart that were not treated by angioplasty or surgery. A special carbon dioxide (CO2) laser is used to create small channels in the heart muscle, improving blood flow in the heart. TMR is a surgical procedure. The procedure is performed through a small left chest incision or through a midline incision. Frequently, it is performed with coronary artery bypass surgery, but occasionally it is performed independently.
Field of Use
Field of use:  Medical Industry primarily used by a heart surgeon.

IPSCIO Record ID: 26860

License Grant
The Company acquired exclusive rights from Licensor, an individual, to a United States patent issued in September 1989, covering a method of reducing mortality associated with chronic CHF in patients with impaired cardiac function by administering a combination of specified amounts of hydralazine and isosorbide dinitrate.
License Property
BIDIL® – an oral dosage formulation containing the combination of hydralazinehydrochloride and isosorbide dinitrate (two generically available vasodilators) – subject to FDA approval, as to which no assurance can be given, proposed to be used to improve symptoms and survival in patients with congestive heart failure (CHF) who are inappropriate for treatment with angiotensin – converting enzyme (ACE) inhibitors.
Field of Use
In March 1993, the Company submitted to the FDA an IND to commence human bioequivalency studies in the U.S.  Phase III clinical testing has been completed.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.